Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders have significant skin in the game with 58% ownership [Yahoo! Finance]
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: Yahoo! Finance
The top 2 shareholders own 56% of the company Institutions own 26% of Cartesian Therapeutics AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To get a sense of who is truly in control of Cartesian Therapeutics, Inc. ( NASDAQ:RNAC ), it is important to understand the ownership structure of the business. We can see that individual insiders own the lion's share in the company with 58% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. With such a notable stake in the company, insiders would be highly incentivised to make value accretive decisions. Let's delve deeper into each type of owner of Cartesian Therapeutics, beginning with the chart below. See our latest analysis for Cartesian Therapeutics NasdaqGM:RNAC Ownership Breakdown November 8th 20
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian Therapeutics (NASDAQ:RNAC) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cartesian Therapeutics (NASDAQ:RNAC) had its price target lowered by analysts at HC Wainwright from $40.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at BTIG Research from $42.00 to $44.00. They now have a "buy" rating on the stock.MarketBeat
- Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Cartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswire
RNAC
Earnings
- 11/6/25 - Miss
RNAC
Analyst Actions
- 11/14/25 - BTIG
RNAC
Sec Filings
- 12/2/25 - Form 4
- 11/19/25 - Form 4
- 11/19/25 - Form 144
- RNAC's page on the SEC website